25-Sep-20 SENSEX 37,388.66[ 835.06 ]Asian Paints 1,924.40 [ 5.20 ]Axis Bank 414.95 [ 12.55 ]Bajaj Auto 2,960.35 [ 29.95 ]Bajaj Finance 3,138.25 [ 110.35 ]Bajaj Finserv 5,798.80 [ 371.60 ]Bharti Airtel 439.70 [ 20.85 ]H D F C 1,651.80 [ 14.00 ]HCL Technologies 827.50 [ 39.45 ]HDFC Bank 1,044.05 [ 14.10 ]Hind. Unilever 2,077.75 [ 17.45 ]ICICI Bank 348.50 [ 12.70 ]IndusInd Bank 514.55 [ 24.35 ]Infosys 1,011.05 [ 35.70 ]ITC 170.80 [ 4.20 ]Kotak Mah. Bank 1,249.45 [ 3.55 ]Larsen & Toubro 889.30 [ 38.95 ]M & M 592.70 [ 18.95 ]Maruti Suzuki 6,496.15 [ 200.30 ]Nestle India 15,734.25 [ 476.40 ]NTPC 84.70 [ 2.05 ]O N G C 68.90 [ 2.50 ]Power Grid Corpn 160.85 [ 1.30 ]Reliance Industr 2,201.70 [ 20.55 ]St Bk of India 182.20 [ 5.75 ]Sun Pharma.Inds. 489.45 [ 4.05 ]Tata Steel 351.90 [ 8.05 ]TCS 2,422.30 [ 90.80 ]Tech Mahindra 772.55 [ 21.20 ]Titan Company 1,109.15 [ 13.40 ]UltraTech Cem. 3,859.50 [ 83.55 ]
 
As on 25-Sep- 2020
Cipla

Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA).

Cipla's Dimethyl Fumarate DR Caps 120mg, 240mg and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc.'s Tecfidera®. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

According to IQVIA (IMS Health), Tecfidera® had US sales of approximately $3.8 Billion for the 12-month period ending July 2020.

The product is available for shipping immediately. Cipla will providing Co-Pay Assistance.

Nestle India

Nestle India will hold a meeting of the Board of Directors of the Company on 23 October 2020.

Duroply Indust.

Duroply Industries has revised the Annual General Meeting of the Company which was scheduled to be held on 28 September 2020. The meeting will now be held on a later date17 October 2020.

Dr Reddy's Labs

Dr Reddys Laboratories announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex® (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Precedex® in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively. The strength is based on the dexmedetomidine base. Containers are intended for single-dose only.

Titan Company

Titan Company announced the resignation of Ireena Vittal (DIN: 005195656), Independent Director of the Company with effect from 01 October 2020.

1 2 3 4 5  ... 
Branches  |  Site Map  |  Disclaimer  |  Margin Files  |  Careers  |  E-Contract Login  |  Fund Transfer
Back Office Login  
Useful Links :  NSE  |  BSE  |  CDSL  |  MCX  |   Scores    
Existing customers can send in their Grievances to : investorgrievance@ssbpl.net '/ response@ssbpl.net
 Terms of Use  |  Rules & Regulations  |  Investor Protection  |  BSE Investor Complaints  |  Statutory Charges  |  PMLA / AML Policy  |  CDSL DP Charges
SEBI Registration Details:

Shilpa Stock Broker Pvt. Ltd.: INZ000201636 | Shikago Trade Pvt. Ltd.: INZ000042135

Research Analyst Registration No.: INH000000776
© Copyright 2011 All Rights Reserved.Shilpa Stock Broker Pvt. Ltd.
Designed, Developed and Powered by C-MOTS Infotech (ISO 9001:2008 certified)